142 related articles for article (PubMed ID: 11833049)
1. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg-->Cys) from a patient with lipoprotein glomerulopathy.
Murano T; Matsumura R; Misawa Y; Ozaki H; Miyashita Y; Yoshida S; Sueioshi M; Sugiyama T; Shirai K
Metabolism; 2002 Feb; 51(2):201-5. PubMed ID: 11833049
[TBL] [Abstract][Full Text] [Related]
2. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
Mitani A; Ishigami M; Watase K; Minakata T; Yamamura T
J Atheroscler Thromb; 2011; 18(6):531-5. PubMed ID: 21325775
[TBL] [Abstract][Full Text] [Related]
3. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
5. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
6. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E isoforms and lipoprotein metabolism.
Phillips MC
IUBMB Life; 2014 Sep; 66(9):616-23. PubMed ID: 25328986
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
Marais AD
Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.
Weisgraber KH
J Lipid Res; 1990 Aug; 31(8):1503-11. PubMed ID: 2280190
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia.
Dergunov AD
Biochemistry (Mosc); 2004 Jul; 69(7):720-37. PubMed ID: 15310270
[TBL] [Abstract][Full Text] [Related]
11. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
Minnich A; Weisgraber KH; Newhouse Y; Dong LM; Fortin LJ; Tremblay M; Davignon J
J Lipid Res; 1995 Jan; 36(1):57-66. PubMed ID: 7706948
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges.
Bentley NM; Ladu MJ; Rajan C; Getz GS; Reardon CA
Biochem J; 2002 Aug; 366(Pt 1):273-9. PubMed ID: 12015813
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding.
Sam R; Wu H; Yue L; Mazzone T; Schwartz MM; Arruda JA; Dunea G; Singh AK
Am J Kidney Dis; 2006 Mar; 47(3):539-48. PubMed ID: 16490634
[TBL] [Abstract][Full Text] [Related]
17. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
19. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
20. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.
Ito K; Nakashima H; Watanabe M; Ishimura A; Miyahara Y; Abe Y; Yasuno T; Ifuku M; Sasatomi Y; Saito T
Nephrol Dial Transplant; 2012 Oct; 27(10):3899-907. PubMed ID: 22863838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
